HemoShear Therapeutics Appoints Brian Wamhoff, PhD, Interim Chief Executive Officer
Dr. Wamhoff is a founder of HemoShear where he co-developed HemoShear’s REVEAL-Tx™ drug discovery platform.
HemoShear
HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer
Industry Veteran Will Lead HST5040 and Future Rare Disease Clinical Program.
Susan Klees Appointed by Governor to Virginia’s Newly Established Rare Disease Council
Susan Klees, HemoShear vice president of communications, has been appointed by Governor Ralph Northam to the Virginia Rare Disease Council.
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
Milestone Achieved by HemoShear in Exclusive Drug Discovery Collaboration.
HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study
HemoShear Therapeutics, Inc. has announced that the first two patients have been dosed in Phase 2 clinical trial of HST5040.
HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio
HemoShear Therapeutics, Inc. has raised $40 million in funding that will enable the company to complete a phase 2 study of its lead compound.
HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia
This award will enable HemoShear to have more frequent interactions with the FDA, as well as eligibility for accelerated approval, priority review, and rolling submission of a new drug application.
Hemoshear Teams Up with Tom Sox
The Tom Sox have been a part of summers in Charlottesvilles since 2015 when they kicked off their inaugural season at Charlottesville High School. This year HemoShear Therapeutics has added...